

Provided by:



Breast Surgery Evidence-Based Literature Review 2023-2024

Breast Surgery Evidence-Based Literature Review 2023-2024 - 3/27/2023 Role of Neoadjuvant Therapy for HR+ Breast Cancer March 27, 2023 4:30 PM - 5:30 PM

Target Audience

This program has been designed for Diagnostic Radiology, Internal Medicine - Medical Oncology, Radiation Oncology, Surgery, Surgery - Complex General Surgical Oncology

Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss and critically evaluate recently published practice-changing, peer-reviewed literature
- 2 Describe new trends and therapeutic modalities in breast surgery
- 3 Discuss and evaluate the nuanced application of research finding into clinical practice scenarios
- 4 Describe how to identify barriers that prevent direct integration of scientific findings into daily patient care

Session Educational Objectives

After completing this educational activity, participants should be able to:

- 1 Discuss general principles of pre-operative therapy
- 2 Describe the significance of pathologic complete in HR+ breast cancer and the average response rates
- 3 Describe neoadjuvant chemotherapy or endocrine therapy

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physicians: Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is for 1.00 contact hours.

Pharmacists: This activity is not approved for pharmacy contact hours

For more information, please contact
Laura Huth, Emily Munroe
No phone on file, (215) 662-2016

laura.huth@penntmedicine.upenn.edu, Emily.Munroe@penntmedicine.upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

PAs: Penn Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

This activity is designated for **1.00** AAPA Category 1 CME credit(s). PAs should only claim credit commensurate with the extent of their participation.

Acknowledgement of Commercial Support*

None

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships (RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant and, applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no relevant financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Leisha C Elmore, MD	Course Director	Nothing to disclose - 01/17/2023
Jennifer Zhang, MD	Course Director	Nothing to disclose - 11/01/2022
Saveri Bhattacharya, DO	Faculty	Consulting Fee-Pfizer, Inc. (Relationship has ended) - 06/06/2022
Kathleen Seidt, CRNP	Nurse Planner	Nothing to disclose - 11/17/2022
Oluwadamilola Fayanju, MD, Associate Professor	Other Planning Committee Member	Nothing to disclose - 07/26/2022
Rebecca Fishman, MD	Other Planning Committee Member	Nothing to disclose - 07/26/2022
Jami D Rothman, MD, FCBC	Other Planning Committee Member	Nothing to disclose - 07/13/2022
Julia Tchou, MD, PhD	Other Planning Committee Member	Advisor-Sensei bio (Relationship has ended) - 08/29/2022
Natashka Wallace, BSN	Other Planning Committee Member	Nothing to disclose - 08/25/2022
Sheri Thrippleton, PA-C	Physician Assistant Planner	Nothing to disclose - 01/11/2023

All relevant financial relationships have been mitigated.

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit where the business lines of the ineligible company relate to the content of the activity. Financial interests are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.